Table 2. Asthma disease characteristics and treatment by practice type and asthma severity in the Malaysian cohort of SABINA III.
|
Disease characteristics |
Primary care (n=265) |
Specialty care (n=466) |
Total (N=732)* |
||
|---|---|---|---|---|---|
|
Mild asthma (n=180) |
Moderate-to-severe asthma (n=85) |
Mild asthma (n=73) |
Moderate-to-severe asthma (n=393) |
||
|
Asthma duration, year, mean (SD) |
23.74 (16.88) |
25.67 (16.25) |
21.95 (17.01) |
23.41 (16.67) |
23.59 (16.69) |
|
GINA treatment step | |||||
|
Step 1 |
37 (20.6) |
0 |
7 (9.6) |
0 |
44 (6.0) |
|
Step 2 |
143 (79.4) |
0 |
66 (90.4) |
0 |
209 (28.6) |
|
Step 3 |
0 |
33 (38.8) |
0 |
111 (28.2) |
144 (19.7) |
|
Step 4 |
0 |
46 (54.1) |
0 |
243 (61.8) |
289 (39.5) |
|
Step 5 |
0 |
6 (7.1) |
0 |
39 (9.9) |
45 (6.1) |
|
Number of severe exacerbations in the previous 12 months, mean (SD) |
1.27 (2.51) |
1.6 (2.32) |
0.92 (1.93) |
1.47 (3.06) |
1.38 (2.76) |
|
No. of patients with severe exacerbations in the previous 12 months, n (%) |
28.19 (5.95) |
29.63 (6.9) |
28.58 (7.74) |
28.74 (6.25) |
28.69 (6.42) |
|
0 |
87 (48.3) |
38 (44.7) |
48 (65.8) |
192 (48.9) |
366 (50.0) |
|
1 |
43 (23.9) |
19 (22.4) |
8 (11.0) |
91 (23.2) |
161 (22.0) |
|
2 |
17 (9.4) |
9 (10.6) |
8 (11.0) |
46 (11.7) |
80 (10.9) |
|
3 |
21 (11.7) |
6 (7.1) |
5 (6.8) |
21 (5.3) |
53 (7.2) |
|
>3 |
12 (6.7) |
13 (15.3) |
4 (5.5) |
43 (10.9) |
72 (9.8) |
|
Asthma symptom control | |||||
|
Well controlled |
93 (51.7) |
50 (58.8) |
46 (63.0) |
210 (53.4) |
400 (54.6) |
|
Partly controlled |
52 (28.9) |
22 (25.9) |
20 (27.4) |
94 (23.9) |
188(25.7) |
|
Uncontrolled |
35 (19.4) |
13 (15.3) |
7 (9.6) |
89 (22.6) |
144 (19.7) |
|
Treatment | |||||
|
SABA alone, n (%) |
32 (17.8) |
0 (0) |
5 (6.8) |
1 (0.3) |
38 (5.2) |
|
Total use in the previous 12 months (canisters/inhalers), mean (SD) |
6.2 (5.9) |
- |
5.4 (6.0) |
3.0 (NA) |
6.0 (5.8) |
|
SABA as add-on to maintenance therapy, n (%) |
148 (82.2) |
74 (87.1) |
64 (87.7) |
294 (74.8) |
580 (79.2) |
|
Total use in the previous 12 months (canisters/inhalers), mean (SD) |
4.7 (4.7) |
3.6 (4.1) |
3.7 (3.3) |
6.0 (5.4) |
5.1 (5.0) |
|
Duration of use, day |
55.3 (47.2) |
29.0 (NA) |
48.0 (15.6) |
60.9 (40.9) |
58.5 (40.1) |
|
ICS, n (%) |
148 (82.2) |
24 (28.2) |
61 (83.6) |
39 (9.9) |
272 (37.2) |
|
Total use in the previous 12 months (canisters/inhalers), mean (SD) |
4.5 (3.6) |
3.0 (2.9) |
5.4 (4.9) |
4.5 (4.5) |
4.6 (4.0) |
|
Total daily dose, n (%) | |||||
|
Low dose |
48 (32.7) |
2 (9.5) |
33 (54.1) |
6 (17.1) |
89 (33.7) |
|
Medium dose |
86 (58.5) |
17 (81) |
27 (44.3) |
28 (80) |
158 (59.8) |
|
High dose |
13 (8.8) |
2 (9.5) |
1 (1.6) |
1 (2.9) |
17 (6.4) |
|
Duration of use, day, mean (SD) |
725.1 (908.1) |
2621.1 (4748.2) |
322.5 (435.6) |
680.9 (1071.6) |
903.6 (2026.9) |
|
ICS/LABA (fixed-dose combination), n (%) |
0 (0) |
71 (83.5) |
14 (19.2) |
384 (97.7) |
470 (64.2) |
|
Total use in the previous 12 months (canisters/inhalers), mean (SD) |
NA |
59.5 (63.4) |
28.2 (56.3) |
42.9 (62.7) |
44.9 (62.8) |
|
Total daily dose, n (%) | |||||
|
Low dose |
NA |
10 (14.3) |
7 (53.8) |
68 (17.8) |
85 (18.2) |
|
Medium dose |
NA |
54 (77.1) |
6 (46.2) |
270 (70.5) |
331 (70.9) |
|
High dose |
NA |
6 (8.6) |
0 (0) |
45 (11.7) |
51 (10.9) |
|
Duration of use, day |
NA |
90.0 (NA) |
50.7 (30.9) |
52.3 (29.4) |
53.2 (29.5) |
|
OCS burst treatment/short course, n (%) |
43 (23.9) |
30 (35.3) |
17 (23.3) |
149 (37.9) |
239 (32.7) |
|
Total daily dose (mg/day), mean (SD) |
30.0 (4.4) |
30.0 (0.0) |
29.1 (3.8) |
39.3 (47.9) |
35.7 (38.2) |
|
Number of days per prescription, mean (SD) |
5.0 (0.7) |
5.0 (1.1) |
4.4 (1.2) |
4.4 (1.4) |
4.6 (1.3) |
|
OCS long-term/maintenance dosing, n (%) |
5 (2.8) |
1 (1.2) |
0 (0) |
24 (6.1) |
30 (4.1) |
|
Total use in the previous 12 months (canisters/inhalers), mean (SD) |
0.0 (0.0) |
0.0 (0.0) |
- |
13.5 (62.5) |
10.7 (55.7) |
|
Total daily dose (mg/day), mean (SD) |
20.0 (44.7) |
200.0 (NA) |
- |
48.2 (85.4) |
48.6 (83.6) |
|
Duration of use, day |
NA (NA) |
NA (NA) |
- |
15.0 (21.2) |
15.0 (21.2) |
|
Antibiotics (prescribed for asthma only), n (%) |
3 (1.7) |
7 (8.4) |
7 (9.6) |
65 (16.5) |
82 (11.3) |
|
Total daily dose (mg/day), mean (SD) |
1658.3 (194.2) |
1178.6 (301.2) |
1453.6 (406.3) |
1550.4 (2230.8) |
1514.3 (1990.9) |
|
Duration of use, day |
0.0 (0.0) |
0.0 (0.0) |
5.2 (12.7) |
2.0 (7.7) |
2.0 (7.6) |
ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; NA, not available; OCS, oral corticosteroid; SABA, short-acting ß2-agonist; SABINA, SABA use IN Asthma; SD, standard deviation.
Data were missing for one patient.